ITCM is a global manufacturer and leading innovator in customised machinery and systems for pharmaceutical packaging and processing.

 

Fusionantibodies' technology offers affordable synthesis of recombinant proteins using high-throughput techniques that enable rapid production and analysis of fusion proteins.

This proprietary technology uses solubility enhancing techniques, developed by Fusion Antibodies, that can be applied to the vast majority of proteins. These proteins can then be used as antigens to give much higher quality antibodies.

The core methodology involves the rapid production of proteins from genes with the gene of interest being cloned into proprietary vectors expressing multiple fusions to rapidly assess solubility. Soluble fusions are identified by high throughput technology, scaled up and purified. The overall timescale from genes to milligram quantities of recombinant protein is typically within 15 days.

Oligonucleotides are designed to the target DNA, which amplify either the full-length coding sequence or relevant epitopes ­ selected in consultation with the client. These DNA target sequences are cloned using unique in-house tag sequences. The fusion proteins are then purified by passage through the relevant column to bind the expressed antigen. Bound protein is then washed, eluted, sequence verified and assessed on SDS/PAGE gels for size and expression and solubility of each fusion protein.

Enter 14 or at www.scientistlive.com/elab

Fusionantibodies Ltd is based In Belfast. www.fusionantibodies.com